14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $39.27 $48.49 Thursday, 2nd May 2024 MRUS stock ended at $47.50. This is 1.02% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 4.29% from a day low at $46.49 to a day high of $48.49.
90 days $35.06 $52.04
52 weeks $18.52 $52.04

Historical Merus NV prices

Date Open High Low Close Volume
May 02, 2024 $47.67 $48.49 $46.49 $47.50 731 865
May 01, 2024 $45.20 $47.86 $45.20 $47.02 759 217
Apr 30, 2024 $45.16 $46.19 $44.38 $44.91 594 032
Apr 29, 2024 $45.18 $46.00 $43.90 $45.11 966 676
Apr 26, 2024 $44.66 $45.84 $44.00 $45.04 819 061
Apr 25, 2024 $41.61 $45.67 $41.11 $44.93 1 912 797
Apr 24, 2024 $41.00 $42.02 $40.60 $41.97 737 700
Apr 23, 2024 $40.89 $41.77 $40.69 $40.82 569 770
Apr 22, 2024 $39.93 $41.50 $39.93 $40.45 703 569
Apr 19, 2024 $40.56 $42.38 $39.27 $39.81 791 764
Apr 18, 2024 $41.06 $41.38 $39.98 $40.47 236 773
Apr 17, 2024 $40.58 $41.54 $40.01 $41.05 401 089
Apr 16, 2024 $41.11 $41.11 $39.70 $40.31 814 445
Apr 15, 2024 $42.32 $42.33 $40.66 $41.27 263 345
Apr 12, 2024 $42.58 $42.71 $41.21 $41.85 305 046
Apr 11, 2024 $42.25 $43.19 $41.99 $43.09 555 480
Apr 10, 2024 $42.42 $42.70 $41.59 $41.74 392 134
Apr 09, 2024 $44.06 $44.37 $42.73 $42.85 766 050
Apr 08, 2024 $44.70 $44.97 $43.96 $44.01 395 144
Apr 05, 2024 $44.09 $45.24 $43.89 $44.70 466 942
Apr 04, 2024 $46.23 $46.42 $44.50 $44.55 373 008
Apr 03, 2024 $44.84 $45.27 $43.96 $44.58 556 315
Apr 02, 2024 $44.35 $45.20 $43.96 $45.20 309 451
Apr 01, 2024 $45.45 $45.60 $43.78 $45.04 420 537
Mar 28, 2024 $44.91 $45.32 $43.87 $45.03 693 617
Click to get the best stock tips daily for free!

About Merus NV

Merus NV Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also de... MRUS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT